Founded in 2012 as a spin-off from Chalmers University of Technology in Sweden, Fluicell is a public biotech company specializing in high resolution bioprinting and single-cell biology. The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate.
The company’s main target group is life sciences researchers at universities as well as within the global pharmaceutical industry and national health laboratories, with a particular focus on cell and membrane research as well as pharmacology.

Fluicell is transforming healthcare through innovative bioprinting and microfluidic research solutions, and tissue-based regenerative medicine, starting from the perspective of the individual cell.

Applications
Biomembrane Printing Application
Cell-to-Cell Molecular Transport Application
Ion Channel Kinetics Application
Isolated Exposure in Brain Slices Application
Single Muscle Fiber Application
Single-Cell Enzymology Application
Single-Cell Viability Application

Products
Lab-on-a-tip
BioPen Systems
Biopixlar Platform
Biopixlar AER
Biozone 6
Dynaflow Resolve System